Three laboratory made opioids derived from kratom became Schedule I controlled substances on August 26, making it a federal crime to manufacture, sell or possess them. The products most consumers actually encounter in gas stations and smoke shops, concentrated 7-hydroxymitragynine gummies, tablets, and shots, were not covered by that order and remain unscheduled.
The temporary scheduling order covers mitragynine pseudoindoxyl, MGM-15, and MGM-16. It runs through August 26, 2028, with a possible one-year extension. A separate proposal covering 7-OH itself above a concentration threshold has not produced an order as of publication.
For households, the gap matters because the packaging does not distinguish between the two categories. A shopper holding a flavored chewable tablet at a convenience store counter has no reliable way to know whether the alkaloid inside became illegal last week or is still openly for sale.
The Order That Took Effect and the One That Did Not
MedicalDaily previously reported that the DEA had told the public in writing when it could begin acting, following two notices of intent. Half of that action has now landed.
What the issuance covers is the three synthetic derivatives. Mitragynine pseudoindoxyl is a chemical rearrangement product of 7-OH, and MGM-15 is a derivative of the same alkaloid. MGM-16 has not been found for sale, but the DEA said online surveillance of a vendor site listed it for upcoming release and that scheduling MGM-15 without it would leave a loophole manufacturers were already positioned to exploit. The agency described the group as potent opioids in its announcement of the scheduling process.
What has not been issued is the order covering 7-OH above a specified threshold, proposed at more than 0.050 percent by weight or volume, or more than 1.00 milligram in a single article. That threshold was written to capture concentrated and processed products while leaving ordinary kratom leaf, which contains only trace amounts, untouched. The Department of Health and Human Services extended the public comment period on that threshold to September 10 after initially closing it on July 31.
None of these actions apply to natural leaf kratom that has not been enhanced. That distinction has been consistent in every federal document so far, including the FDA’s consumer page on 7-OH products.
Fatal Cases Behind the Federal Finding
The DEA justified the order on an imminent hazard finding, and the surveillance figures it cited are stark.
Through its toxicology testing program, the agency identified mitragynine pseudoindoxyl in at least 56 overdose cases between February 2025 and May 2026, of which 48 were fatal. MGM-15 appeared in 17 overdose cases from February through April 2026, 16 of them fatal. Forensic laboratories logged 19 reports of mitragynine pseudoindoxyl across Arkansas, New York, Ohio and Wyoming.
The wider trend is worse. A CDC analysis published in the Morbidity and Mortality Weekly Report found kratom-related calls to U.S. poison centers rose more than 1,200 percent, from 258 in 2015 to 3,434 in 2025, with 14,449 reports over eleven years.
Potency explains part of it. In animal studies, MGM-15 was roughly 50 times more potent than morphine and MGM-16 roughly 240 times. Mitragynine pseudoindoxyl was about 100 times more potent than mitragynine at the mu opioid receptor. These are potent opioid agonists, which means a risk profile similar to prescription opioids: respiratory depression, physical dependence, and withdrawal.
Packaging Built to Look Like a Snack
The federal record on how these products are sold is unusually blunt, and it is the part parents should read.
A study cited by the DEA examined 51 products sold online as mitragynine pseudoindoxyl. Seventy-six percent were chewable tablets. Thirty-five carried flavors including berry, mint, watermelon, pink lemonade, candy apple, grape, mango and vanilla bean. Thirty-two used brightly colored packaging. Two were dried ice cream cones, and one was a chocolate bar. Seventy-one percent contained a combination of mitragynine pseudoindoxyl and 7-OH rather than a single compound.
The agency named brands including Kama, Hydroxie, Fruity Perks and Happie Tabs as market context. Prices ran roughly two to four dollars per tablet, which the DEA said could accelerate frequent use and dose escalation.
Marketing language did the rest. Products were sold as botanical extracts, mood boosters and clean alternatives to prescription opioids, while some of the same retail listings carried warnings about dependence, overdose and death. Many are sold with no age restriction.
Withdrawal Risk and Where to Get Help
The people most exposed are daily users, and the immediate practical risk for them is not prosecution but supply.
When products vanish from shelves, dependence becomes withdrawal on a schedule set by federal action rather than a clinical plan. A published case report described a 34 year old man who escalated from powdered kratom to 7-OH tablets and then to mitragynine pseudoindoxyl, eventually taking nine 20 milligram doses a day. He scored 31 on the clinical opiate withdrawal scale, a severe rating, with high blood pressure, rapid heart rate, tremors and gastrointestinal distress, and needed supportive medication over three to four days.
Anyone using these products regularly should talk to a clinician before stopping abruptly rather than after. Opioid use disorder is treatable, and the medications that work for other opioids are relevant here. SAMHSA operates a free, confidential national helpline at 1-800-662-4357. Local health departments and federally qualified health centers can connect people to treatment on a sliding fee scale.
Several things remain unresolved. Whether and when the 7-OH threshold order will be issued is unknown. Temporary scheduling orders are not subject to judicial review, so this action cannot be challenged in court the way a permanent rule could. Several states have passed kratom consumer protection laws, and others restrict 7-OH products outright, so local rules may already be stricter than federal ones.
Anyone who suspects an opioid overdose, marked by slowed or stopped breathing, blue lips or unresponsiveness, should call 911 and give naloxone if available.
Related MedicalDaily.com Coverage
DEA Could Ban Concentrated 7-OH Kratom Products Any Time After August 5, What Consumers Need to Know
A Fat Burner Sold Online Hides An Antidepressant In Its Day Pills And A Pesticide At Night
Key Questions Answered
What became illegal? Mitragynine pseudoindoxyl, MGM-15 and MGM-16 entered Schedule I on August 26, 2026, for two years with a possible one year extension.
Are concentrated 7-OH gummies and shots now banned? Not by this order. A separate proposal covering 7-OH above a concentration threshold has not produced a scheduling order as of publication.
Does any of this affect plain kratom leaf? No. Every federal document so far has excluded natural leaf that has not been enhanced with added or concentrated 7-OH.
How dangerous are these compounds? They are potent mu opioid receptor agonists. In animal studies, MGM-15 was about 50 times and MGM-16 about 240 times more potent than morphine.
What do the overdose numbers show? DEA surveillance identified mitragynine pseudoindoxyl in at least 56 overdose cases with 48 fatal, and MGM-15 in 17 cases with 16 fatal.
Why is this hard for shoppers to spot? Products are sold as flavored chewables in bright packaging under names like Fruity Perks, often marketed as botanical extracts, with many containing more than one opioid alkaloid.
What should a regular user do? Speak with a clinician before stopping, because withdrawal can be severe. SAMHSA’s national helpline is 1-800-662-4357.
